Lab Compound Boosts Fat Burning Without Muscle Loss in Mice
Elena Vasquez · Medical Content Editor
November 21, 2026 · 1 min read
Most weight loss drugs on the market today, including GLP-1 medications like Ozempic and Wegovy, work by reducing appetite. A new animal study from the University of California, Berkeley, explores a different strategy: raising the amount of energy the body burns rather than cutting calorie intake.
According to the university's release on ScienceDaily, researchers tested a molecule known as TOFA, an ACC inhibitor that interferes with fat production while also switching on genes that help the body burn fat for fuel. In obese mice, TOFA raised energy expenditure by as much as 18 percent, even though the animals were not more physically active and their body temperature did not rise. The treated mice also became more sensitive to insulin, had lower triglycerides, showed improvement in fatty liver changes, and lost fat without the notable drop in lean muscle mass often seen with appetite suppressing drugs.
Combining TOFA with existing GLP-1 treatments produced stronger results than either approach alone, the researchers reported. Earlier ACC inhibitors stalled in development because they tended to raise blood triglycerides, so the team is now investigating why TOFA seems to avoid that problem. The compound has not been tested in humans, and its safety and effectiveness in people remain unknown.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.


